Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort : data from the CERERRA collaboration

Show full item record



Permalink

http://hdl.handle.net/10138/164978

Citation

Chatzidionysiou , K , Lie , E , Nasonov , E , Lukina , G , Hetland , M L , Tarp , U , Ancuta , I , Pavelka , K , Nordstrom , D C , Gabay , C , Canhao , H , Tomsic , M , van Riel , P L C M , Gomez-Reino , J , Kvien , T K , van Vollenhoven , R F & Rheumatic Dis Portuguese Register 2016 , ' Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort : data from the CERERRA collaboration ' , Arthritis research & therapy , vol. 18 , 50 . https://doi.org/10.1186/s13075-016-0951-z

Title: Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort : data from the CERERRA collaboration
Author: Chatzidionysiou, Katerina; Lie, Elisabeth; Nasonov, Evgeny; Lukina, Galina; Hetland, Merete Lund; Tarp, Ulrik; Ancuta, Ioan; Pavelka, Karel; Nordstrom, Dan C.; Gabay, Cem; Canhao, Helene; Tomsic, Matija; van Riel, Piet L. C. M.; Gomez-Reino, Juan; Kvien, Tore K.; van Vollenhoven, Ronald F.; Rheumatic Dis Portuguese Register
Contributor: University of Helsinki, Clinicum
Date: 2016-02-16
Language: eng
Number of pages: 6
Belongs to series: Arthritis research & therapy
ISSN: 1478-6354
URI: http://hdl.handle.net/10138/164978
Abstract: Background: The approved dose of rituximab (RTX) in rheumatoid arthritis is 1000 mg x 2, but some data have suggested similar clinical efficacy with 500 mg x 2. The purpose of this study was to compare the effectiveness of the regular and low doses given as first treatment course. Methods: Twelve European registries participating in the CERERRA collaboration (The European Collaborative Registries for the Evaluation of Rituximab in Rheumatoid Arthritis) submitted anonymized datasets with demographic, efficacy and treatment data for patients who had started RTX. Treatment effectiveness was assessed by DAS28 reductions and EULAR responses after 6 months. Results: Data on RTX dose were available for 2,873 patients, of whom 2,625 (91.4 %) and 248 (8.6 %) received 1000 mg x 2 and 500 mg x 2, respectively. Patients treated with 500 mg x 2 were significantly older, had longer disease duration, higher number of prior DMARDs, but lower number of prior biologics and lower baseline DAS28 than those treated with 1000 mg x 2. Fewer patients in the low-dose group received concomitant DMARDs but more frequently received concomitant corticosteroids. Both doses led to significant clinical improvements at 6 months. DAS28 reductions at 6 months were comparable in the 2 dose regimens [mean DeltaDAS28 +/- SD -2.0 +/- 1.3 (high dose) vs. -1.7 +/- 1.4 (low dose), p = 0.23 adjusted for baseline differences]. Similar percentages of patients achieved EULAR good response in the two dose groups, 18.4 % vs. 17.3 %, respectively (p = 0.36). Conclusions: In this large observational cohort initial treatment with RTX at 500 mg x 2 and 1000 mg x 2 led to comparable clinical outcomes at 6 months.
Subject: Rituximab
Rheumatoid arthritis
Observational
MONOCLONAL-ANTIBODY
PLUS METHOTREXATE
CONTROLLED-TRIAL
JOINT DAMAGE
DOUBLE-BLIND
EFFICACY
SAFETY
DEPLETION
THERAPY
INHIBITION
3121 Internal medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Effectiveness_of_two_different_doses.pdf 712.0Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record